Browse > Article
http://dx.doi.org/10.14348/molcells.2015.2256

Structural Identification of a Non-Glycosylated Variant at Ser126 for O-Glycosylation Site from EPO BRP, Human Recombinant Erythropoietin by LC/MS Analysis  

Byeon, Jaehee (Deptatment of Stereoscopic Media, Korean German Institute of Technology)
Lim, Yu-Ri (BIOnSYSTEMS, Inc., R&D Center)
Kim, Hyong-Ha (Center for Bioanalysis, Korea Research Institute of Standards and Science)
Suh, Jung-Keun (Deptatment of Stereoscopic Media, Korean German Institute of Technology)
Publication Information
Molecules and Cells / v.38, no.6, 2015 , pp. 496-505 More about this Journal
Abstract
A variant peak was detected in the analysis of RP-HPLC of rHu-EPO, which has about 7% relative content. Fractions of the main and the variant peaks were pooled separately and further analyzed to identify the molecular structure of the variant peak. Total mass analysis for each peak fraction using ESI-TOF MS shows differences in molecular mass. The fraction of the main peak tends to result in higher molecular masses than the fraction of the variant. The detected masses for the variant are about 600-1000 Da smaller than those for the main peak. Peptide mapping analysis for each peak fraction using Asp-N and Glu-C shows differences in O-glycopeptide profiles at Ser126. The O-glycopeptides were not detected in the fraction of the variant. It is concluded that the variant peak is non-O-glycosylated rHu-EPO and the main peak is fully O-glycosylated rHu-EPO at Ser126.
Keywords
erythropoietin; O-glycosylation; total mass analysis; Peptide Mapping;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Castilho, A., Neumann, L., Daskalova, S., Mason, H. S., Steinkellner, H., Altmann, F., and Strasser, R. (2012). Engineering of sialylated mucin-type O-glycosylation in plants. J. Biol. Chem. 287, 36518-36526.   DOI
2 Cazzola, M., Mercuriali, F., and Brugnara, C. (1997). Use of recombinant human erythropoietin outside the setting of uremia. Blood 89, 4248-4267.
3 Council of Europe. (2007). European Pharmacopoeia, 6th eds. (Strasbourg, France: Council of Europe).
4 Davis, J.M., Arakawa, T., Strickland, T.W., and Yphantis, D.A. (1987). Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 26, 2633-2638.   DOI   ScienceOn
5 Delorme, E., Lorenzini, T., Giffin, J., Martin, F., Jacobsen, F., Boone, T., and Elliott, S. (1992). Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry 31, 9871-9876.   DOI   ScienceOn
6 Dudkiewicz-Wilczynska, J., Snycerski, A., and Tautt, J. (2002). Application of high-performance size exclusion chromatography to the determination of erythropoietin in pharmaceutical preparations. Acta pol. Pharm. 59, 83-86.
7 Elliott, S., Egrie, J., Browne, J., Lorenzini, T., Busse, L., Rogers, N., and Ponting, I. (2004). Control of rHuEPO biological activity: the role of carbohydrate. Exp. Hematol. 32, 1146-1155.   DOI   ScienceOn
8 Fukuda, M.N., Sasaki, H., Lopez, L., and Fukuda, M. (1989). Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 73, 84-89.
9 Gimenez, E., Ramos-Hernan, R., Benavente, F., Barbosa, J., and Sanz-Nebot, V. (2012). Analysis of recombinant human erythropoietin glycopeptides by capillary electrophoresis electrospray- time of flight-mass spectrometry. Anal. Chim. acta 709, 81-90.   DOI   ScienceOn
10 Goldwasser, E., and Kung, C.K. (1968). Progress in the purification of erythropoietin. Ann. N Y Acad. Sci. 149, 49-53.   DOI
11 Gong, B., Burnina, I., Stadheim, T.A., and Li, H. (2013) Glycosylation characterization of recombinant human erythropoietin produced in glycoengineered Pichia pastoris by mass spectrometry. J. Mass Spectrom. 48, 1308-1317.   DOI   ScienceOn
12 Hokke, C.H., Bergwerff, A.A., Dedem, G.W., Kamerling, J.P., and Vliegenthart, J.F. (1995). Structural analysis of the sialylated N-and O-linked carbohydrate chains of recombinant human erythropoietin expressed in chinese hamster ovary cells. Eur. J. Biochem. 228, 981-1008.   DOI
13 Kolarich, D., Jensen, P.H., Altmann, F., and Packer, N.H. (2012). Determination of site-specific glycan heterogeneity on glycoproteins. Nat. Protoc. 7, 1285-1298.   DOI   ScienceOn
14 Llop, E., Gutierrez-Gallego, R., Segura, J., Mallorqui, J., and Pascual, J.A. (2008). Structural analysis of the glycosylation of gene-activated erythropoietin (epoetin delta, Dynepo). Anal. Biochem. 383, 243-254.   DOI   ScienceOn
15 Rane, S.S., Ajameri, A., Mody, R., and Padmaja, P. (2012). Development and validation of RP-HPLC and RP-UPLC methods for quantification of erythropoietin formulated with human serum albumin. J. Pharm. Anal. 2, 160-165.   DOI   ScienceOn
16 Spivak, J.L. (1998). The biology and clinical applications of recombinant erythropoietin. Semin. Oncol. 25, 7-11.
17 Sasaki, H., Bothner, B., Dell, A., and Fukuda, M. (1987). Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J. Biol. Chem. 262, 12059-12076.
18 Sasaki, H., Ochi, N., Dell, A., and Fukuda, M. (1988). Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment-mass spectrometry. Biochemistry 27, 8618- 8626.   DOI   ScienceOn
19 Song, K.E., Byeon, J., Moon, D.B., Kim, H.H., Choi, Y.J., and Suh, J.K.(2014) Structural identification of modified amino acids on the interface between EPO and its receptor from EPO BRP, human recombinant erythropoietin by LC/MS analysis. Mol. Cells 37, 819-826.   DOI   ScienceOn
20 Spivak, J.L., and Hogans, B.B. (1989). The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 73, 90-99.
21 Stubiger, G., Marchetti, M., Nagano, M., Grimm, R., Gmeiner, G., Reichel, C., and Allmaier, G. (2005). Characterization of N-and O-glycopeptides of recombinant human erythropoietins as potential biomarkers for doping analysis by means of microscale sample purification combined with MALDI-TOF and quadrupole IT/RTOF mass spectrometry. J. Cell. Sci. 28, 1764-1778.
22 Sytkowski A.J. (2004). Erythropoietin: blood, brain and beyond (Weinheim, Germany: Wiley-VCH Verlag).
23 Toyoda, T., Itai, T., Arakawa, T., Aoki, K.H., and Yamaguchi, H. (2000). Stabilization of human recombinant erythropoietin through interactions with the highly branched N-glycans. J. Biochem. 128, 731-737.   DOI   ScienceOn
24 Wilczynska, J.D., Roman, I., and Anuszewska, E. (2005). The separation of EPO from other proteins in medical products formulated with different stabilizers. Acta Pol. Pharm. 62, 177-182.
25 Tsuda, E., Kawanishi, G., Ueda, M., Masuda, S., and Sasaki, R. (1990). The role of carbohydrate in recombinant human erythropoietin. Eur. J. Biochem. 188, 405-411.   DOI   ScienceOn
26 Wasley, L.C., Timony, G., Murtha, P., Stoudemire, J., Dorner, A.J., Caro, J., Krieger, M., and Kaufman, R.J. (1991). The importance of N-and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin. Blood 77, 2624-2632.